Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
- Japan Looks to Start Pediatric COVID-19 Vaccinations from February
November 19, 2021
- Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Vynmac Listing OK’ed, but Chuikyo Urges Response to Market Expansion with Similar Upgrade
November 18, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- MHLW Panel to Discuss Idorsia’s Cerebral Vasospasm Drug on Nov. 26; Efient Up for Review Again
November 17, 2021
- Sclerosing Cholangitis Added to ADR List in Tecentriq Label
November 17, 2021
- MSD’s Noxafil Price to Be Trimmed 0.5% under CEA Scheme
November 17, 2021
- Takeda’s Cell Therapy Alofisel Gets 5.62 Million Yen Price Tag
November 17, 2021
- 50 Billion Yen-Plus Peak Sales Projected for Pfizer’s Vynmac, Listing Set for Nov. 25
November 17, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Chuikyo Subcommittee OKs Basic SaMD Reimbursement Rule
November 16, 2021
- PMDA’s SaMD Consultation Desk Handling 30 Inquiries per Month
November 16, 2021
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- Pharma Calls for Enhancing Pre-Analysis Discussions in CEA Scheme: Chuikyo
November 15, 2021
- Japan to Reinstate HPV Vaccine Recommendation after 8 Years in Limbo
November 15, 2021
- Govt to Provide Up to 2 Billion Yen per Oral COVID-19 Drug to Support Development
November 15, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…